HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million. On the news front, according to reports from pharmaceutical research networks, the 2026 ASCO GI conference is scheduled to take place from January 8 to January 10, 2026, with the official release of abstract contents for this Gastrointestinal Cancers Symposium. Notably, HENLIUS has for the first time disclosed clinical data from its Phase II study of the PD-L1 ADC drug candidate HLX43 for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC). HLX43 is a novel ADC drug targeting PD-L1, which combines the dual mechanisms of immune checkpoint inhibition and cytotoxic effects. Its Phase I clinical trial has already demonstrated promising efficacy and a favorable safety profile in patients who did not respond to prior immunotherapy. This Phase II study is designed to evaluate the efficacy and safety of HLX43 in patients with previously treated recurrent or metastatic esophageal squamous cell carcinoma.